Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Johnson & Johnson : J&J Cancer Drug Zytiga Now Backed For Publicly Funded Use In UK

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/16/2012 | 11:11am CEST

The U.K.'s health-care cost-effectiveness regulator Wednesday reversed an earlier decision and approved the publicly funded use of Johnson & Johnson's (JNJ) prostate-cancer pill Zytiga, after the U.S. company cut its price further.

Also known as abiraterone, Zytiga removes the prostate cancer tumor's supply of testosterone, preventing it from growing further and potentially extending a patient's life by more than three months. The medicine was rejected for use in the U.K. in February on grounds its terms of use wouldn't offer value for money.

Andrew Dillon, chief executive of the U.K.'s National Institute for Health and Clinical Excellence, or NICE, Wednesday said the manufacturer subsequently submitted fresh information, including a revised patient access scheme containing a deeper price discount to the National Health Service and more information about which patients would most benefit from its use and how many patients could receive the drug.

"These factors enabled the committee to revise its preliminary recommendation and now recommend the drug for use on the NHS," Dillon said in a statement. "It is an effective treatment, potentially extending life by more than three months, and it also allows patients to be treated at home as it can be taken orally."

Abiraterone costs GBP2,930 for a 30-day supply of 120 tablets. NICE didn't specify the size of the price cut offered by Johnson & Johnson.

Zytiga was approved by U.S. and European drug regulators last year. It is set to generate peak-year sales of $910 million.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
02:41a DXB ENTERTAINMENTS : DDB Dubai appoints Iris Minnema as MD
06/23 JOHNSON & JOHNSON : State investigates drug makers
06/23 JOHNSON & JOHNSON : Donald Trump picks Woody Johnson to be US ambassador to Brit..
06/22 JOHNSON & JOHNSON : Innovation Announces New Collaborations Advancing Ground-Bre..
06/22 BRISTOL MYERS SQUIBB : Supreme Court ruling could make it harder to file class-a..
06/22 MARKETS RIGHT NOW : After early stumble, stocks drift higher
06/22 JOHNSON & JOHNSON : Completes Acquisition of Actelion, a Leader in Pulmonary Hyp..
06/22 JOHNSON & JOHNSON : Releases 2016 Health for Humanity Report
06/22 JOHNSON & JOHNSON : Missouri AG files suit against three opioid manufacturers
06/22DJR. JOHNSON : Missouri Sues Drug Firms Over Opioid Marketing -- WSJ
More news
Sector news : Pharmaceuticals - NEC
06/23DJSAMSUNG ELECTRONICS : Makes Play for Drug Market With Version of Humira -- Updat..
06/23DJSAMSUNG ELECTRONICS : Makes Big Play in Drug Market With Cheaper Version of Bloc..
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/23 China's ICBC says checks of loans to big acquirers are routine
06/22 GSK'S NEW CEO AIMS TO DIVEST SPORTS : sources
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
06/23 Look Out Below - Tax Issues Could Catch ALIOY Holders By Surprise
06/22 I Bought The 7.65% Yield But Only Fools Are Buying The 8.16% Yield
06/22 8.76% Dividend Yield Whoops Brothers 8.61%
06/22 Only Bristol Bucks Big Pharma's Drive For External Reliance
06/22 Market Is Divided Between Growth And Value - Cramer's Mad Money (6/21/17)
Advertisement
Financials ($)
Sales 2017 75 604 M
EBIT 2017 23 480 M
Net income 2017 17 895 M
Debt 2017 8 106 M
Yield 2017 2,46%
P/E ratio 2017 20,81
P/E ratio 2018 18,69
EV / Sales 2017 4,97x
EV / Sales 2018 4,73x
Capitalization 367 520 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 132 $
Spread / Average Target -3,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON18.42%366 496
NOVARTIS13.09%225 516
ROCHE HOLDING LTD.8.68%225 056
PFIZER5.20%202 832
MERCK AND COMPANY12.38%180 576
SANOFI14.27%124 760
More Results